商业化培养基|奥浦迈-细胞培养基和端到端CDMO解决方案

经典培养基

奥浦迈为您提供质量稳定、产能灵活、货期可控的DMEM、DMEM/F-12、RPMI 1640等经典基础培养基，可满足科学研究和基于细胞培养的大规模生物制品的生产。

产品特点：

产品信息表

使用奥浦迈产品发表的文献

Raddeanin A Improves the Therapeutic Effect of Osimertinib in NSCLC by Accelerating ROS/NLRP3-mediated Pyroptosis
Current Pharmaceutical Design, 2023 October 13.
Caspase-mediated LPS sensing and pyroptosis signaling in Hydra
Science advances, 2023, 9(29): eadh4054.
Safety and immunogenicity of a modified COVID19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial
Life Metabolism, 2023, 2(3): load019.
Tumor invasion inhibition of thiophene substituted long chain chalcones
Chinese Pharmacological Bulletin. 2018; (12): 467-472,.